Neumora Therapeutics, Inc. (NMRA)
0.6767
-0.03
(-3.75%)
USD |
NASDAQ |
Sep 25, 16:00
0.70
+0.02
(+3.44%)
After-Hours: 19:59
Neumora Therapeutics Research and Development Expense (Annual) : 176.06M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 176.06M |
| December 31, 2024 | 200.93M |
| December 31, 2023 | 142.72M |
| December 31, 2022 | 91.75M |
| Date | Value |
|---|---|
| December 31, 2021 | 55.78M |
| December 31, 2020 | 17.61M |
| December 31, 2019 | 0.00 |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| BioAge Labs, Inc. | 73.97M |
| LB Pharmaceuticals, Inc. | 16.74M |
| ANI Pharmaceuticals, Inc. | 51.66M |
| Corcept Therapeutics, Inc. | 254.91M |
| Veru, Inc. | 15.59M |